(Reuters) - Olympic 800 meters champion Caster Semenya filed an appeal to Switzerland’s highest court on Wednesday against rules requiring middle-distance female athletes with a high natural level of testosterone to reduce it via medication.
“I am a woman and I am a world-class athlete. The IAAF (International Association of Athletics Federations) will not drug me or stop me from being who I am,” the 28-year-old South African said in a statement after lodging the appeal.
In a case splitting opinion in women’s sport, Semenya lost an appeal to the Court of Arbitration for Sport (CAS) on May 1 which ruled the IAAF’s rules were necessary for athletes with differences in sexual development (DSDs) to ensure fair competition.
Semenya’s statement added that she will ask the Swiss Federal Supreme Court to set aside CAS’s decision in its entirety, which it said did not consider medical protocols and uncertain health consequences of taking testosterone-reducing medication.
Under the new regulations, female athletes with high natural levels of testosterone wishing to compete in events from 400 meters to a mile must medically limit that level to under five nmol/L, double the normal female range of below two nmol/L.
Semenya has repeatedly stated she will not take medication to comply with the regulations, which came into effect on May 8, but she has also vowed to continue to compete in the 800 meters.
Testosterone is a hormone that increases muscle mass, strength and hemoglobin - which affects endurance.
Semenya won her last competitive 800 meter race at a Diamond League meeting in Doha on May 3 and has pledged to return to Qatar to defend her world title in September, but the regulations will not allow her to compete unless she takes medication.
Semenya, who also races 5,000 meters, could continue to compete in longer distances not affected by the rule change but she has vowed to continue her fight to stay competing in the 800 meters, which she recently said was her calling.
Reporting by Richard Martin; Editing by Ed Osmond and Andrew Cawthorne